Xenon files azetukalner NDA; X-NOVA2 topline set for Q1 2027
Xenon Pharmaceuticals says it has filed an NDA for azetukalner as an adjunctive focal seizure treatment and expects X-NOVA2 topline data in Q1 2027, without further timing details.
Xenon Pharmaceuticals says it has filed an NDA for azetukalner as an adjunctive focal seizure treatment and expects X-NOVA2 topline data in Q1 2027, without further timing details.